Oral solithromycin: Phase II started

Cempra began an open-label, U.S. Phase II trial to evaluate once-daily 400 mg oral solithromycin for 13 weeks in up to 15 patients ages 18-70 with NASH without cirrhosis. Cempra has exclusive rights t...